SynBiotic SE (ETR:SBX)

Market Cap	21.24M
Revenue (ttm)	3.86M
Net Income (ttm)	-10.63M
Shares Out	n/a
EPS (ttm)	-2.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	515
Average Volume	4,143
Open	3.080
Previous Close	3.130
Day's Range	3.050 - 3.080
52-Week Range	2.550 - 10.250
Beta	5.24
RSI	45.22
Earnings Date	May 16, 2025

About SynBiotic SE

SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. The company was formerly known as Ledgertech SE and changed its name to SynBiotic SE. SynBiotic SE was incorporated in 2024 and is based in Munich, Germ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2024
• Employees: 55
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: SBX

Financial Performance

In 2023, SynBiotic SE's revenue was 3.86 million, a decrease of -52.71% compared to the previous year's 8.17 million. Losses were -10.63 million, -56.36% less than in 2022.